12:00 AM
 | 
Jun 04, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Xalkori crizotinib: Phase I data

Data from an expansion cohort of 13 advanced NSCLC patients with a c-ros oncogene 1 ( ROS1) rearrangement, 12 of whom were ALK-negative, in a Phase I trial showed that twice-daily 250 mg oral Xalkori led to an ORR of 54%, including 1 complete response and 6...

Read the full 219 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >